1. Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
- Author
-
Lorenza Landi, Antonio Passaro, Rita Chiari, Francesco Grossi, Marcello Tiseo, Paolo Bidoli, Luca Toschi, Angelo Delmonte, Hector Soto Parra, Luana Calabrò, Diego Signorelli, Francesco Gelsomino, Diana Giannarelli, Francovito Piantedosi, F. D'Incà, Federico Cappuzzo, Domenico Galetta, Alain Gelibter, Gabriele Minuti, Maria Rita Migliorino, Francesco Cognetti, Landi, L, D'Inca, F, Gelibter, A, Chiari, R, Grossi, F, Delmonte, A, Passaro, A, Signorelli, D, Gelsomino, F, Galetta, D, Giannarelli, D, Soto Parra, H, Minuti, G, Tiseo, M, Migliorino, M, Cognetti, F, Toschi, L, Bidoli, P, Piantedosi, F, Calabro', L, and Cappuzzo, F
- Subjects
0301 basic medicine ,Oncology ,Male ,Cancer Research ,Lung Neoplasms ,Cohort Studies ,0302 clinical medicine ,Antineoplastic Agents, Immunological ,Carcinoma, Non-Small-Cell Lung ,80 and over ,Immunology and Allergy ,Medicine ,Molecular Targeted Therapy ,Prospective cohort study ,Non-Small-Cell Lung ,Aged, 80 and over ,Clinical Trials as Topic ,Tumor ,Bone metastasis ,Bone metastases ,Immunotherapy ,Nivolumab ,Non-small-cell lung cancer ,PD-L1 ,Adult ,Aged ,Biomarkers, Tumor ,Bone Neoplasms ,Female ,Humans ,Middle Aged ,Prognosis ,Treatment Outcome ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Immunological ,030220 oncology & carcinogenesis ,Cohort ,Molecular Medicine ,Research Article ,Cohort study ,medicine.medical_specialty ,Immunology ,Antineoplastic Agents ,lcsh:RC254-282 ,03 medical and health sciences ,Internal medicine ,Progression-free survival ,Lung cancer ,Pharmacology ,Performance status ,business.industry ,Carcinoma ,medicine.disease ,Bone metastase ,030104 developmental biology ,Expanded access ,business ,Biomarkers - Abstract
Background Bone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic organ actively regulating immune system. We hypothesized that BoM may influence sensitivity to immunotherapy. Methods Pretreated non-squamous (cohort A) and squamous (cohort B) NSCLCs included in the Italian Expanded Access Program were evaluated for nivolumab efficacy according to BoM. Results Cohort A accounted for 1588 patients with non-squamous NSCLC, including 626 (39%) with (BoM+) and 962 (61%) without BoM (BoM-). Cohort B accounted for 371 patients with squamous histology including 120 BoM+ (32%) and 251 (68%) BoM- cases. BoM+ had lower overall response rate (ORR; Cohort A: 12% versus 23%, p
- Published
- 2019